FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen

Glenmark bags FDA nod for generic asthma inhaler with 180-day exclusivity

Medi Assist teams up with LawtonAsia to bring AI-powered health-tech to Southeast Asia

The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region

Zenex Animal Health makes strategic European play with VievePharm acquisition

VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets

Emcure partners with Roche to boost nephrology and transplant care in India

Emcure to distribute Roche's kidney transplant and anemia drugs in India

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases